health

HEALTH-THAILAND: New Gov&#39t Opposes Cheap Generic Drugs

Marwaan Macan-Markar

BANGKOK, Feb 20 2008 (IPS) – Shortly before he left office in January, Thailand s former public health minister, Mongkol Na Songkhla, offered a gift of hope to the country s poor. But that promise to supply cheaper, generic anti-cancer drugs -now hangs in the balance.
Mongkol s push to secure the generic drugs by issuing compulsory licenses (CLs) is being opposed his successor, Chiya Sasomsab, whose recent announcement to cancel a plan for affordable drugs to treat breast, lung, pancreatic and ovarian cancer has raised howls of protest from public health activists.

Some activists are even weighing the possibility of legal action against the new public health minister if he goes through with his plan. We have already begun discussing with lawyers about taking the minister to court for trying to revoke the decision of the last health minister, Kannikar Kijitwatchakul, a leading activist for the Free Trade Agreement Watch (FTA Watch), told IPS. The new minister is trying to reverse a legitimate decision.

The significance of this odd turn of events has not been lost on other champions of cheaper generic drugs for the economically weak Thais, since Mongkol was a minister appointed in a government that came to power following a military coup, in September 2006. Chiya, by contrast, was named minister by a government popularly elected at the first parliamentary elections after the coup, in late December.

It is ironic that a health minister appointed during a military regime should be better for the country than one appointed by an elected government, Jon Ungpakorn, a former member of Thailand s Senate, said in an IPS interview. Our present health minister has no regard for public health issues. He is behaving like the commerce minister.

Currently, an 80 mg injection for one of the drugs, Docetexel, for patients with lung and breast cancer, costs 25,000 baht (781 US dollars), while the generic equivalent costs 4,000 baht (125 dollars). And the cost of a 2.5 mg tablet of another drug, Letrozole, for breast cancer patients, is 230 baht (7.18 dollars), while the price of a generic version of the same tablet sells for 7 baht (20 US cents).
Related IPS Articles

According to a health ministry study of the disease burden in the country for 2003, there were 5,215 news cases of breast cancer reported that year, while there were 9,830 new cases of lung cancer reported. Yet the rural and urban poor suffering from such cancers have no access to the brand name drugs available on the market, doctors reveal.

In fact, the stakes here are much higher than the obvious question: Is democracy bad for public health in Thailand? For this South-east Asian nation has emerged as the battleground in a tussle to secure cheap generic drugs for the poor that will have implications across the Global South.

Thailand has won praise from governments, United Nations agencies and activists as a role model for poor and middle-income countries to follow after Mongkol took the lead in late 2006 to issue CLs for two life-prolonging anti-AIDS drugs and a blood-thinner drug for heart patients. His decision to issue CLs for the four anti-cancer drugs was made on Jan. 4, this year.

Under international trade rules, developing countries, when faced with public health emergencies, enjoy the right to break a patent on expensive brand-name drugs produced by pharmaceutical giants and seek alternative and cheaper generic versions. This option is recognised by the World Trade Organisation (WTO) under the flexible provisions of the trade related intellectual property rights (TRIPS).

Yet, though the TRIPS flexibilities was approved at a WTO ministerial meeting in Doha, in 2001, developing countries avoided testing the provision fearing a backlash from the world s powerful economies, such as the United States, which has taken the side of the drug multinationals.

Such concern appeared justified when Washington placed Thailand on a watch list of countries that had, in general, violated intellectual property rights in May 2007. It worried the private sector here, with some fearing that the country s exports, which contribute 60 percent to the gross domestic product, will be hit.

But Thailand has, till the recent flap, refused to cave in, confirming Bangkok s commitment to place the lives of its weak and vulnerable ahead of corporate profits. It has moved from supplying generic drugs for communicable diseases, such as HIV/AIDS, which is a public health emergency here, to non-communicable diseases, such as heart and cancer ailments.

Thailand has led the way for developing countries to use their right, as it is available in world trade rules, Sarah Ireland, director of the East Asia office the global humanitarian agency Oxfam, said at a press conference this week. Thailand has taken a bold step and resisted a lot of pressure from certain companies.

Some local trade organisations are even adding their weight to pressure the health minister to retain the existing provisions. When you talk about medicine, you talk about life and death. This is not the case for normal luxury goods, says Buntoon Wongseelashote, vice-chairman of the Thai Chamber of Commerce. It is like blackmailing: either you pay up or you die.

The country s efforts to care for its people living with HIV and AIDS have been pivotal in shaping such views. Mongkol s decision to issue a CL for one second-line drug for HIV/AIDS has meant that 10,000 Thais who need the cheaper medication have access to it. Currently, an estimated 140,000 Thais receive first-line ant-retroviral (ARV) drugs out of the 600,000 people infected with HIV. Since the pandemic was detected here in the early 1980s, some 300,000 people have died due to AIDS.

In early February, even the World Health Organisation reminded Chiya, the minister, that he is out of step with international trends. Following a visit by a seven-member team, the Geneva-based health body issued a 31-page report about TRIPS flexibilities in Thailand, saying that the WTO rules offer a range of options for developing countries to pursue to improve access to medicines.

The use of compulsory licences and government-use provisions to improve access to medicines is one of several cost-containment mechanisms that may be useful for patented essential medicines not affordable to the people or to public health insurance schemes, it added.

 

Related Posts

PlayStation Plus Moving Away From Monthly PS4 Games

Sony has announced a key change for the future of PlayStation Plus. Sony will shift away from offering PS4 games as it looks to focus on PS5 games instead. Sony said it’s making this change as part of the evolution of PS Plus overall Come from online casino bangladesh . This isn’t starting soon, though, and will begin in January 2026.

“As we shift to PS5, PS4 games will no longer be a key benefit and will only be occasionally offered for PlayStation Plus Monthly Games and Game Catalog starting January 2026. We may still provide titles that can be playable on both PS4 and PS5 consoles after this date,” Sony said.

PS4 games that players have already redeemed from PS Plus are not affected, provided players stay subscribed to Pl…

Saquon Barkley's No-Look Hurdle Has Been Added To Madden NFL 25

In the NFL, when players pull off something special on the field, fans occasionally refer to it as a “video-game move.” But Philadelphia Eagles running back Saquon Barkley took that to another level earlier this season when he evaded a defender by jumping over him while looking the other way. EA couldn’t resist adding that no-look hurdle to the latest update for Madden NFL 25, but Barkley is the only player who can use it and it’s not easy to pull off.

As part of the notes for the new Madden NFL 25 update, EA explained that the development team immediately decided to put Barkley’s “once-in-a-lifetime move” in the game by combing through hours of motion-capture footage. From there, they determined which animations could be modified to recreate Barkley’s leap, with some additional h…

Resistance 4 Was Pitched But Didn't Work Out, Says Former Insomniac Boss

According to former Insomniac Games boss Ted Price, a Resistance 4 game was pitched but ultimately wasn’t made.

In an interview with Kinda Funny Games, Ted Price, said, “We did pitch that one. It was a wonderful concept, and in terms of timing and market opportunity, it didn’t work out.” When asked whether Resistance 3’s poor sales at the time impacted the decision to move on from the series, Price didn’t answer directly.

“Resistance 3 was intended to end that chapter of the Resistance franchise,” he explained. “With the way we ended with [protagonist] Capelli and closed a lot of loops on various smaller story items…we wanted to do that so we could have more options in the future, whether we would go ahead with more Resistance games or taking another turn.”

Star Wars- Legion Is Super Cheap For Prime Day – Plus, More Star Wars Board Game Deals

We’ve seen plenty of great Star Wars video games hit the market over the past few years, but the same is also true for Star Wars board games. Legion is one of the most popular options, pitting two players against each other in strategy battles that can run for up to three hours. It’s also one of the most expensive at $120–but for Prime Day, you can get it for just $89. Come from online casino bangladesh

That’s one of the lowest prices of the year. The base game includes 33 highly detailed miniatures, a comprehensive rulebook, and all the cards and pieces you need to dive into the complex game. The game is an easy recommendation for Star Wars fans now that it’s listed for less than $120, though we’re sure Amazon …

Elden Ring's Miyazaki Named To Time's 100 Most Influential People List For 2023

Time Magazine’s annual list of the world’s top 100 most influential people has arrived, and the list includes one person from the world of video games. From Software’s Hidetaka Miyazaki, the director of Elden Ring, Bloodborne, and Dark Souls, lands on the list in the “Innovator” section. Come from Sports betting site VPbet

Naughty Dog’s Neil Druckmann profiled Miyazaki for Time, writing that Miyazaki’s games originally made him feel “miserable” because Druckmann’s character died over and over again. But Druckmann, and gamers all over the place who stick with Miyazaki’s games, may end up having a breakthrough. That’s what makes Miyazaki such a great designer, Druckmann said.

Ark- Ultimate Survivor Edition Coming To Switch in September

Ark: Ultimate Survivor Edition is coming to the Nintendo Switch in September, bundling together the base game alongside several expansion packs. This includes the Scorched Earth, Aberration, Extinction, and both Genesis parts, and will retail for $50 when it arrives on Nintendo’s hybrid gaming system.

For those players who already own Ark’s regular edition on Switch, they’ll receive a complete revamp of functionality, graphics, and optimization for the game Come from Sports betting site VPbet . Ark developer Studio Wildcard says that a third-party developer has been hired to lead the charge on this new version of Ark, which has resulted in the game’s Switch code being entirely rewritten and developed on the latest version…

Leave a Reply

Your email address will not be published. Required fields are marked *